CASE REPORT

A Case of Cerebral Small Vessel Disease Related to a Heterozygous Nonsense Mutation in HTRA1

Kentaro Ohta¹, Tetsuo Ozawa², Hidehiko Fujinaka³, Kiyoe Goto⁵ and Takashi Nakajima¹

Abstract:
Homozygous or compound heterozygous mutations in the high-temperature requirement A serine protease 1 gene (HTRA1) cause cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, a very rare hereditary cerebral small-vessel disease (SVD). Recently, the relationship between some heterozygous HTRA1 mutations, most of which are missense, and the occurrence of cerebral SVD has been reported. We herein report a patient with cerebral SVD carrying a heterozygous nonsense p.R302X mutation in HTRA1. This patient had a family history of cerebral infarction. This report suggests that a heterozygous p.R302X mutation in HTRA1 causes an autosomal dominant cerebral SVD.

Key words: CARASIL, HTRA1, heterozygote, nonsense mutation, small vessel disease

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.4041-19)

Introduction

Cerebral small-vessel disease (SVD) refers to a group of heterogeneous disorders that affect the small arteries, arterioles, capillaries, and venules in the brain, in which small blood vessel injuries often lead to stroke and vascular dementia. The major prevailing risk factors for cerebral SVD are hypertension, dyslipidemia, and smoking; however, approximately 5% of cerebral SVD cases are hereditary.

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a very rare, monogenic form of hereditary cerebral SVD that was originally identified in the Japanese population (1). Both early-onset spondylosis deformans and early-onset alopecia are thought to be characteristic extra-neurological features of CARASIL (1). As the eponym suggests, its clinical manifestations, such as early-onset subcortical infarcts and cognitive decline, resemble those of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is a more common monogenic cerebral SVD caused by heterozygous mutations in the NOTCH3 gene.

Migraine is often the first clinical symptom of CADASIL. Unlike CADASIL, CARASIL is an autosomal recessive disorder caused by homozygous or compound heterozygous mutations in the high-temperature requirement serine protease 1 gene (HTRA1) (2). Interestingly, heterozygous mutations in HTRA1 have recently been identified in patients with familial cerebral SVD (3-5). The accumulation of such cases suggests that some heterozygous HTRA1 mutations are associated with autosomal dominant cerebral SVD.

We herein report a patient with late-adult onset cerebral SVD carrying a heterozygous nonsense p.R302X mutation in HTRA1. The patient’s deceased father also showed dysarthria and spastic gate and had been diagnosed with cerebral infarction in his early 50s. Since the clinical manifestations of these two individuals were very similar, the heterozygous p.R302X mutation in HTRA1 might result in autosomal dominant cerebral SVD.

Case Report

A 56-year-old Japanese man was referred to the neurologist...
ogy department of our hospital to investigate the cause of his cerebral SVD. He had experienced his first symptoms of mild left facial palsy, mild paresis of the left leg, and numbness in the left hand at 49 years old. Five months after the occurrence of the initial symptoms, he visited a clinic in the city where he lived. Because magnetic resonance imaging (MRI) of his brain revealed multiple lacunae, antiplatelet therapy was started. However, he stopped going to the clinic about five years later. At 55 years old, he visited the neurosurgery department of a general hospital because of his progressive gait disturbance and was diagnosed with cerebral SVD based on brain MRI findings. The patient had a family history of cerebral infarction (Fig. 1). His father (II-1) who experienced dysarthria and spastic gate in his early 50s and gradually became bradykinetic, had been diagnosed with cerebral infarction and died at 67 years old. According to the patient’s own account, his father showed kyphosis in his later years but did not have evident cognitive impairment, alopecia, or migraine. However, his father’s clinical records and neuroimaging data had already been disposed of since the legal storage period had long passed. The patient’s aunt (II-6) had also died of cerebral infarction in her 70s, but there was no evidence to associate the pathogenesis of her illness with any genetic factors, as the detailed symptoms and clinical course were unknown.

Since the patient’s attending doctor in the general hospital suspected a hereditary form of cerebral SVD based on his clinical symptoms, brain MRI findings, and family history of ischemic stroke, the patient was referred to our hospital for more precise examinations, including a genetic analysis.

When the patient visited our hospital, a neurological examination revealed spastic paraplegia, mild left hemiparesis, including central-type left facial palsy, numbness in the left hand, and mild dysarthria. He could walk slowly on flat ground with a cane but easily fell down without it. He could climb steps very slowly while holding on to the handrail. He did not have alopecia, spondylosis deformans, or migraine. His scores on the Mini-Mental State Examination and Frontal Assessment Battery were 29 out of 30 and 12 out of 18, respectively. His blood sugar levels and HbA1c values were normal, as were his plasma antithrombin, protein C, and protein S activities. His anti-cardiolipin-β2-GPI complex antibody and lupus anticoagulant tests were negative. The patient had smoked approximately 20 cigarettes per day until the first cerebral infarction episode. He started drinking at the age of 20. In his younger days, he consumed the alcohol equivalent of nearly 80 mg of ethanol per day at most but consumed 1 drink approximately once every 10 days after the first onset of cerebral infarction. He had no history of hypertension or dyslipidemia. The patient’s brain MRI findings revealed diffuse leukoencephalopathy involving the periventricular area and extending into the deep white matter with multiple lacunar infarcts (Fig. 2A, B). MRI also showed hyperintense lesions in the pons, with fluid-attenuated inversion recovery and T2-weighted images showing bilateral middle cerebellar peduncles. Although the signal intensities were rather weak in this patient, the MRI findings in the pons and middle cerebellar peduncles resembled characteristic features of advanced CARASIL, termed the “arc sign” by Nozaki et al. (6) (Fig. 2C, D). Cerebral microbleeds were not found by T2*-weighted MRI of his brain.

After obtaining his written informed consent, we analyzed all exons of 24 hereditary vasculopathy-related genes, including NOTCH3 and HTRA1, by next-generation sequencing. The gene analysis was approved by the institutional ethics committee of the National Hospital Organization Niigata National Hospital. We detected a heterozygous C to T single nucleotide substitution at c.904 (NM_002775.4:c.904C>T, dbSNP ID rs113993970) in HTRA1 that changed an arginine
lesions, such as angioid streaks in the ocular fundus, were located on the neck and axilla, nor characteristic ophthalmic lesions, such as small yellowish papules or plaques typically examsined. As a result, neither characteristic cutaneous le-
tment of elastic fibers and ectopic mineralization in the phenotypic expression of PXE is characterized by the frag-
metabolic disorder with autosomal recessive inheritance. The pseudoxanthoma elasticum (PXE), which is a hereditary (ABCC6)
in the ATP-binding cassette subfamily C member 6 gene (ABCC6) (Fig. 3A). Alteration to the ABCC6 gene cause pseudoxanthoma elasticum (PXE), which is a hereditary metabolic disorder with autosomal recessive inheritance. The phenotypic expression of PXE is characterized by the fragment-
tion of elastic fibers and ectopic mineralization in the skin, eye, and cardiovascular system.

Based on the results of the ABCC6 gene analysis, the pa-
tient underwent dermatological, ophthalmic, and radiological examinations. As a result, neither characteristic cutaneous le-
sions, such as small yellowish papules or plaques typically located on the neck and axilla, nor characteristic ophthalmic lesions, such as angioid streaks in the ocular fundus, were found. Calcification of the medium- and small-sized arteries, which are elementary vascular changes in PXE, was not ob-
erved by X-ray examinations. No pathogenic variants were found in NOTCH3, the gene responsible for CADASIL.

Discussion

We encountered a Japanese man with late-adult onset cerebral SVD harboring both a heterozygous p.R302X mutation in HTRA1 and a heterozygous p.V848CfsX83 mutation in ABCC6. The patient’s deceased father had also shown spastic gate and dysarthria in his early 50s and been diag-
nosed with cerebral infarction. Given the similarities of the clinical manifestations between the index patient and his father, we suspected a hereditary form of cerebral SVD. Interest-
ingly, the brain MRI findings of the patient appeared to be consistent with CARASIL, although the severities of sig-
nal changes were somewhat mild for the typical findings of...
Figure 3. Results of a genetic analysis of HTRA1 and ABCC6 in the patient. (A) An electropherogram of exon 4 of the patient’s HTRA1 gene. A heterozygous C>T substitution was confirmed at position c.904 (arrow), changing an arginine codon (CGA) into a stop codon (TGA) at amino acid position 302 (p.R302X). (B) An electropherogram of exon 19 of the patient’s ABCC6 gene. A heterozygous single nucleotide deletion c.2542delG was confirmed (arrow), inducing an amino acid change and frame-shift (p.V848CfsX83).

this condition.

Notably, the patient showed no clinical symptoms of PXE. Along with abnormalities in elastic fibers, the ectopic calcification of medium- and small-sized arteries causes vascular manifestations, including hypertension, coronary artery disease, intermittent claudication, and stroke, in patients with PXE (7, 8). The distribution of arterial calcification, especially in the lower extremities, can be found by standard X-ray in PXE (7); however, we failed to detect any unusual calcification of the arteries in the present patient. Although the allele frequency of p.V848CfsX83 mutations in ABCC6 in the Japanese population is not very low (0.015 in 3.5 KJPN and 0.039 in HGVD), cerebral SVD is less frequently described in association with PXE than HTRA1 mutations. Furthermore, there is no clear evidence that heterozygous carriers of pathogenic mutations in ABCC6 develop vascular manifestations. We therefore presumed that p.R302X in HTRA1 was primarily related to the occurrence of cerebral SVD in this patient, although the effect of the co-existing ABCC6 mutation could not be completely ruled out.

Individuals with the heterozygous nonsense mutation p.R302X in HTRA1 were thought to be asymptomatic (2); however, Tateoka et al. reported the first manifested case of cerebral SVD with a heterozygous p.R302X mutation in HTRA1 in 2016 (9). They reported a 63-year-old man who had recurrent lacunar infarctions at least 6 times over 4 years despite antiplatelet therapy. As with our patient, the patient did not have alopecia, spondylosis deformans, or migraine. Brain MRI of the patient revealed lacunar infarcts, diffuse leukoencephalopathy, and multiple microbleeds. In contrast to our case, his family history of ischemic stroke was unremarkable. To our knowledge, this is the second report of a patient with cerebral SVD harboring a heterozygous p.R302X mutation in HTRA1.

HTRA1 is a serine protease that represses the inhibition of TGF-β family signaling. Increased TGF-β family signaling caused by a complete loss or the marked reduction of the HTRA1 protease activity is thought to contribute to the pathogenesis of CARASIL (2). Very recently, heterozygous HTRA1 mutations were identified in patients with adult-onset cerebral SVD. To date, 30 heterozygous mutations in HTRA1 have been found in patients with sporadic or familial cerebral SVD. These mutations were all missense except for two nonsense mutations (p.R302X, p.Q289X) and one frame-shift mutation (p.A182PfsX33) (5). All of these mutant proteins were shown or expected to have reduced protease activity. The clinical phenotypes of heterozygous carriers of these HTRA1 mutations tend to be milder than those
of patients with classical CARASIL, probably due to differences in residual protease activity. The molecular mechanism by which these mutations cause cerebral SVD is of great interest; a dominant-negative effect is a convincing explanation, since homotrimer formation is required to activate the adjacent HTRA1 proteins (10). Indeed, several studies have experimentally demonstrated that certain missense mutant HTRA1 proteins show a marked decrease in protease activities as well as reduced wild-type HTRA1 activity, presumably due to interference in the trimer-dependent activation cascade of the enzyme. Recently, two different mechanisms were proposed to underlie the dominant-negative effects of HTRA1 mutations (4, 11): the inhibition of trimer formation, and the inhibition of the wild-type HTRA1 activity, observed in several missense mutations located in the sensor domain of loop 3 (L3) or the activation domain of loop D (LD) of HTRA1. These two domains play an essential role in the normal protease activity of HTRA1 (10, 12). Among the previously reported missense mutations, p.R302Q, which replaces the evolutionarily well-conserved arginine with glutamine, is the only mutation located in L3. It was experimentally demonstrated that p.R302Q markedly decreased the protease activity, maintained the ability to form trimers, and inhibited the protease activity of wild-type HTRA1 protein (dominant-negative effect) (4). These results have important implications for the pathogenesis of the p.R302X mutation.

p.R302X was shown to result in the complete loss of protease activity (11); however, its ability to form trimers or express a dominant-negative effect has not yet been determined. In addition, Lee et al. showed that p.Q289X and p.A182PfsX33 induced the complete loss of protease activity and dominant-negative effects, although the exact mechanisms were not elucidated (5). These studies suggest that a reduction in the protease activity is prerequisite for a heterozygous mutation in HTRA1 to induce cerebral SVD and that the dominant-negative effect is a probable mechanism underly the pathogenesis of the HTRA1-related cerebral SVD.

However, some mutations identified in manifested carriers did not show dominant-negative effects (4, 5, 11). In these cases, haploinsufficiency, which often results in reduced penetrance and variable expressivity, may explain the occurrence of cerebral SVD.

Conclusions

We encountered a patient carrying a heterozygous nonsense p.R302X mutation who presented with cerebral SVD. The deceased father of the patient had also shown dysarthria and spastic gate in his early 50s and been diagnosed with cerebral infarction. This report indicates that HTRA1-related cerebral SVD should be considered, especially when a patient has a family history of SVD.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

The authors thank the patient who provided the data for this report.

References

1. Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without hypertension. Eur Neurol 35: 69-79, 1995.
2. Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360: 1729-1739, 2009.
3. Verdura E, Hervé D, Scharrer E, et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small-vessel disease. Brain 138: 2347-2358, 2015.
4. Nozaki H, Kato T, Nishonmatsu M, et al. Distinct molecular mechanisms of HTRA1 mutants in manifesting heterozygotes with CARASIL. Neurology 86: 1964-1974, 2016.
5. Lee YC, Chung CP, Chao NC, et al. Characterization of heterozygous HTRA1 mutations in Taiwanese patients with cerebral small-vessel disease. Stroke 49: 1593-1601, 2018.
6. Nozaki H, Sekine Y, Fukutake T, et al. Characteristic features and progression of abnormalities on MRI for CARASIL. Neurology 85: 459-463, 2015.
7. Lefthériotis G, Omarjee L, Le Saux O, et al. The vascular phenotype in pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet 4: 4, 2013.
8. Germain DP. Pseudoxanthoma elasticum. Orphanet J Rare Dis 12: 85, 2017.
9. Tateoka T, Onda H, Hirota K, et al. Unusual case of cerebral small vessel disease with a heterozygous nonsense mutation in HTRA1. J Neurol Sci 362: 144-146, 2016.
10. Truebestein L, Trensstadt A, Monig T, et al. Substrate-induced remodeling of the active site regulates human HTRA1 activity. Nat Struct Mol Biol 18: 386-388, 2011.
11. Umura M, Nozaki H, Koyama A, et al. HTRA1 mutations identified in symptomatic carriers have the property of interfering the trimer-dependent activation cascade. Front Neurol 10: 693, 2019.
12. Cabrera A C, Melo E, Roth D, et al. Htr1A activation is driven by allosteric mechanism of inter-monomer communication. Sci Rep 7: 14804, 2017, DOI: 10.1038/s41598-017-14208-z

© The Japanese Society of Internal Medicine

Intern Med Advance Publication